May 14 (Reuters) - Mayne Pharma Group Ltd (MYX) :
- EXPECTS 4QFY19 TO BE STRONGER DRIVEN BY REBOUND IN GENERIC PRODUCTS
- JAN-APRIL REPORTED REVENUE $154.1 MILLION, DOWN 15%
- JAN-APRIL GENERIC PRODUCTS $88.9 MILLION, DOWN 32%
News: MYX Mayne Pharma Expects Q4 To Be Stronger Driven By Rebound In Generic Products
-
- There are more pages in this discussion • 65 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.37 |
Change
-0.010(0.23%) |
Mkt cap ! $371.7M | |||
| Open | High | Low | Value | Volume |
| $4.39 | $4.44 | $4.35 | $309.7K | 70.59K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 544 | $4.37 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.39 | 139 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| MYX (ASX) Chart |